Chrysalis

Chrysalis operates as an infrastructure-as-a-service provider in the life sciences sector, offering turnkey, customizable GMP cleanroom suites and ancillary support services. The company's core value proposition is providing biotech firms with speed, flexibility, and control over their manufacturing, enabling them to launch production in weeks without long-term capital commitments. With facilities in key biotech hubs (Burlington, MA; Waltham, MA; Raleigh, NC), Chrysalis targets companies in drug delivery and biologics seeking to de-risk and accelerate their path to clinical trials and commercialization. Its partnership with bioX aims to expand its platform of GMP infrastructure and technical GxP services.

Integrated GMP cleanroom hosting platform offering configurable ISO 7 suites, in-house environmental monitoring, GMP cleaning, and warehouse storage as a flexible service.

Chrysalis competes in the niche of flexible GMP infrastructure. Direct competitors include other cleanroom hosting providers and spec GMP facility developers. It also competes indirectly with full-service CDMOs for clients who prefer more control, and with traditional real estate leases where tenants build out their own space. Its differentiation lies in its integrated service model, speed-to-occupancy, and emphasis on client autonomy without long-term lock-ins.